CRIS - Curis, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.1100
+0.0500 (+4.72%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.0600
Open1.0800
Bid0.00 x 1000
Ask0.00 x 1100
Day's Range1.0600 - 1.1500
52 Week Range0.6000 - 5.2000
Volume175,268
Avg. Volume394,709
Market Cap36.756M
Beta (3Y Monthly)0.78
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire13 days ago

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., Jan. 4, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 2, 2019, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 30,000 shares of Curis common stock to a new employee, with a grant date of January 2, 2019 (the "Q1 2019 Inducement Grant").

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire2 months ago

    Curis to Present at the 60th Annual Meeting of the American Society of Hematology

    LEXINGTON, Mass. , Nov. 20, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, ...

  • PR Newswire2 months ago

    Curis to Present at 33rd Society for Immunotherapy of Cancer Annual Meeting and Cowen IO NEXT Summit

    LEXINGTON, Mass. , Nov. 7, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, ...

  • PR Newswire3 months ago

    Curis Reports Third Quarter 2018 Financial Results

    LEXINGTON, Mass., Nov. 1, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2018. "Following Curis's recent leadership change, we are increasing our focus on the clinical execution of our three first-in-class therapeutics that have the potential to be significant and innovative cancer treatments. "To achieve this goal, we are re-allocating resources to prioritize clinical operations and have implemented a reduction in headcount and expenditure on pre-clinical science, pipeline expansion, and general and administrative expenses.

  • PR Newswire3 months ago

    Curis to Release Third Quarter Financial Results and Hold Conference Call on November 1, 2018

    LEXINGTON, Mass., Oct. 23, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2018 financial results on Thursday, November 1, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. ET. Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors.

  • GlobeNewswire3 months ago

    Investor Expectations to Drive Momentum within Ormat Technologies, The Andersons, Freshpet, Curis, Ultra Clean, and Edge Therapeutics — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire3 months ago

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., Oct. 5, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that on October 1, 2018, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 30,000 shares of Curis common stock to a new employee, with a grant date of October 1, 2018 (the "Q4 2018 Inducement Grant"). The Q4 2018 Inducement Grant has an exercise price per share equal to the closing price of the Company's common stock on October 1, 2018. The stock option has a 10 year term and vests over four years, with 25% of the original number of shares underlying the award vesting on the first anniversary of the employee's date of hire and an additional 6.25% of the original number of shares underlying the award vesting on each successive three-month period thereafter, subject to the employee's continued service with the Company through the respective vesting dates.  The stock option was granted as an inducement equity award outside of the Company's Third Amended and Restated 2010 Stock Incentive Plan and was made as an inducement material to the employee's acceptance of employment with the Company.

  • PR Newswire4 months ago

    Curis to Present at the Cantor Fitzgerald Global Healthcare Conference

    James Dentzer, the Company's new President & Chief Executive Officer, will provide a brief overview of the Company's pipeline of drug candidates and business strategy. A live webcast of the presentation will be available by visiting the investor section of Curis' website http://investors.curis.com/events-and-presentations.

  • PR Newswire4 months ago

    Curis Announces Leadership Change

    LEXINGTON, Mass., Sept. 24, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced a change in leadership with the appointment of James E. Dentzer as President and Chief Executive Officer effective immediately. In addition, Mr. Dentzer will become a member of the Curis Board of Directors. Mr. Dentzer, who joined Curis in 2016, was promoted earlier this year to Chief Operating Officer to manage all functions outside of research and development, including business development, manufacturing, quality, human resources, finance, legal, IT, and investor and public relations.

  • PR Newswire5 months ago

    Curis to Present at the Baird 2018 Global Healthcare Conference

    LEXINGTON, Mass., Aug. 28, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will present at the Baird 2018 Global Healthcare Conference on Wednesday, September 5 at 2:35-3:05 PM in Session III - Empire Ballroom B, Mezzanine Level of the InterContinental New York Barclay in New York. The presentation will be held using a fireside-chat format in which Ali Fattaey, Ph.D. President and Chief Executive Officer, will provide a brief overview of the Company's pipeline of drug candidates and business strategy, after which an equity analyst will moderate a question and answer session. A live webcast of the presentation will be available by visiting the investors section of Curis' website http://investors.curis.com/events-and-presentations.

  • PR Newswire6 months ago

    Curis Reports Second Quarter 2018 Financial Results

    -- Management to host conference call today at 8:30 a.m. EDT -- LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization ...

  • PR Newswire6 months ago

    Curis to Release Second Quarter Financial Results and Hold Conference Call on August 2, 2018

    LEXINGTON, Mass., July 27, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2018 financial results on Thursday, August 2, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT. Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the PDL1/VISTA antagonist CA-170, and the PDL1/TIM3 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene.

  • PR Newswire6 months ago

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., July 9, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that on July 2, 2018, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 12,000 shares of Curis common stock to a new employee, with a grant date of July 2, 2018 (the "Q3 2018 Inducement Grant"). Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors.  Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology.  As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the PDL1/VISTA antagonist CA-170, and the PDL1/TIM3 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948.  CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene.  CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma.  Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.

  • ACCESSWIRE8 months ago

    Curis Shares Show Recent Gains, Pipeline Review and FDA Decision

    NEW YORK, NY / ACCESSWIRE / June 1, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Curis, Inc. (CRIS) is a biotechnology company, focused on the development and commercialization of drug candidates for the treatment of human cancers. Curis announced that its previously disclosed 1-for-5 reverse stock split will be effective as of 5:00 p.m. Eastern Time today, May 29, 2018. Curis's common stock will begin trading on the Nasdaq Global Market on a split-adjusted basis when the market opened on Wednesday, May 30, 2018.

  • PR Newswire8 months ago

    /C O R R E C T I O N -- Curis, Inc./

    In the news release, Curis Announces FDA Fast Track Designation for Fimepinostat (CUDC-907) Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, issued 31-May-2018 by Curis, ...

  • PR Newswire8 months ago

    Curis Announces Effectiveness of 1-for-5 Reverse Stock Split

    LEXINGTON, Mass., May 29, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that its previously disclosed 1-for-5 reverse stock split will be effective as of 5:00 p.m. Eastern Time today, May 29, 2018.  Curis's common stock will begin trading on the Nasdaq Global Market on a split-adjusted basis when the market opens on Wednesday, May 30, 2018.  The new CUSIP number for Curis's common stock following the reverse stock split is 231269 200. The reverse stock split affects all issued and outstanding shares of Curis's common stock, as well as the number of shares of common stock available for issuance under the Company's equity incentive plans.  The reverse stock split will reduce the number of shares of the Curis's issued and outstanding common stock from approximately 337,500,000 million to approximately 67,500,000 million.  In addition, the reverse stock split will effect a reduction in the number of shares of common stock issuable upon the exercise of stock options outstanding immediately prior to the reverse stock split, with a proportional increase in exercise price.  The reverse stock split will proportionately reduce the number of authorized shares of common stock.

  • PR Newswire8 months ago

    Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development

    LEXINGTON, Mass., May 24, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that Robert Martell, M.D., Ph.D., has been appointed Head of Research and Development. In this newly created role, Dr. Martell, a practicing oncologist and experienced drug developer, will directly manage the day-to-day operations of the Curis clinical development and research efforts. Dr. Martell is a member of the Board of Directors of Curis, and will resign from his board duties simultaneous with his start date on June 1st.

  • PR Newswire8 months ago

    Curis Announces 1-for-5 Reverse Stock Split

    LEXINGTON, Mass., May 22, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that its Board of Directors approved a 1-for-5 reverse split of Curis's common stock that is expected to take effect on Tuesday, May 29, 2018 after the close of trading. The reverse stock split will affect all holders of common stock uniformly and will not alter any stockholder's percentage ownership interest in Curis, except to the extent that the reverse stock split would result in a stockholder owning a fractional share.

  • PR Newswire9 months ago

    Curis Reports First Quarter 2018 Financial Results

    -- Management to host conference call today at 8:30 a.m. EDT -- LEXINGTON, Mass. , May 3, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization ...

  • PR Newswire9 months ago

    Curis to Release First Quarter 2018 Financial Results and Hold Conference Call on May 3, 2018

    LEXINGTON, Mass., April 26, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2018 financial results on Thursday, May 3, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT. Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors.